Fotemustine for the treatment of melanoma

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Coory M, Baade P, Aitken J, Trends for in situ and invasive melanoma in Queensland, Australia, 1982 – 2002. Cancer Causes Control 2006;17:21-7
   PubMed Web of Science ®Google Scholar
• Downing A, Yu XQ, Newton-Bishop J, Forman D. Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003. Int J Cancer 2008;123:861-6
   PubMedGoogle Scholar
• Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001;93:678-83
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Johnson TM, Dolan OM, Hamilton TA, Clinical and histologic trends of melanoma. J Am Acad Dermatol 1998;38:681-6
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
   PubMed Web of Science ®Google Scholar
• Buttner P, Garbe C, Bertz J, Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995;75:2499-506
   PubMed Web of Science ®Google Scholar
• Bichakjian CK, Halpern AC, Johnson TM, AAD (American Academy of Dermatology). Guidelines of Care for the Management of Primary Cutaneous Melanoma. 2011. Available from: http://www.aad.org/education-and-quality-care/clinical-guidelines/current-and-upcoming-guidelines [Last Accessed October 2011]
   Google Scholar
• NHMRC (National Health and Medical Research Council). Clinical Practice Guidelines for the Management of Cutaneous Melanoma. 1999. Available from: http://www.nhmrc.gov.au/publications/synopses/cp68syn.htm [Last Accessed October 2011]
   Google Scholar
• SIGN (Scottish Intercollegiate Guidelines Network). Cutaneous melanoma. 2003. Available from: http://www.sign.ac.uk/pdf/sign72.pdf [Last Accessed October 2011]
   Google Scholar
• Negrier S, Saiag P, Guillot B, Guidelines for clinical practice: Standards, options and recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations. Ann Dermatol Venereol 2005;132(10 Suppl):13-85
   PubMedGoogle Scholar
• Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 364:1738-45
   PubMedGoogle Scholar
• Morton DL, Cochran AJ, Thompson JF, Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-11
   PubMed Web of Science ®Google Scholar
• Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part II. J Am Acad Dermatol 2010;62:737-48; quiz 749-50
   PubMedGoogle Scholar
• Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part I. J Am Acad Dermatol 2010;62:723-34; quiz 735-6
   PubMed Web of Science ®Google Scholar
• Klein O, Schmidt C, Knights A, Melanoma vaccines: developments over the past 10 years. Expert Rev Vaccines 2011;10:853-73
   PubMed Web of Science ®Google Scholar
• Dreno B, Nguyen JM, Khammari A, Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51:539-46
   PubMed Web of Science ®Google Scholar
• Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;11:75-81
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu PY, Lee SJ, Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34
   PubMed Web of Science ®Google Scholar
• Naumann SC, Roos WP, Jost E, Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009;100:322-33
   PubMed Web of Science ®Google Scholar
• Roos WP, Jost E, Belohlavek C, Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-beta and valproic acid. Cancer Res 2011;71:4150-60
   PubMedGoogle Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Ribas A, Kim KB, Schuchter LM, BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation positivemelanoma. J Clin Oncol 2011;29:8509
   Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• Tapiero H, Yin MB, Catalin J, Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036. Anticancer Res 1989;9:1617-22
   PubMedGoogle Scholar
• Tong WP, Kirk MC, Ludlum DB. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N'-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 1982;42:3102-5
   PubMed Web of Science ®Google Scholar
• Gander M, Leyvraz S, Decosterd L, Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 1999;10:831-8
   PubMed Web of Science ®Google Scholar
• Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007;6:1079-99
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Citti L, Taverna P, Catapano CV. Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988;15:279-92
   PubMed Web of Science ®Google Scholar
• Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990;50:6119-29
   PubMed Web of Science ®Google Scholar
• Passagne I, Evrard A, Winum JY, Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. J Pharmacol Exp Ther 2003;307:816-23
   PubMed Web of Science ®Google Scholar
• Christmann M, Pick M, Lage H, Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001;92:123-9
   PubMed Web of Science ®Google Scholar
• Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta 2011;1816:179-90
   PubMed Web of Science ®Google Scholar
• Gordon BH, Richards RP, Hiley MP, A new method for the measurement of nitrosoureas in plasma: an HPLC procedure for the measurement of fotemustine kinetics. Xenobiotica 1989;19:329-39
   PubMed Web of Science ®Google Scholar
• Meulemans A, Giroux B, Hannoun P, Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Chemotherapy 1989;35:313-19
   PubMed Web of Science ®Google Scholar
• Meulemans A, Giroux B, Hannoun P, Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy 1991;37:86-92
   PubMed Web of Science ®Google Scholar
• Khayat D, Giroux B, Berille J, Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 1994;12:414-20
   PubMed Web of Science ®Google Scholar
• Tranchand B, Lucas C, Biron P, Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. Cancer Chemother Pharmacol 1993;32:46-52
   PubMed Web of Science ®Google Scholar
• Khayat D, Lokiec F, Bizzari JP, Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987;47:6782-5
   PubMed Web of Science ®Google Scholar
• Fischel JL, Formento P, Etienne MC, In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother Pharmacol 1990;25:337-41
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Wood JM. Sensitivity and resistance in human metastatic melanoma to the new chloroethylnitrosourea anti-tumor drug Fotemustine. Biochim Biophys Acta 1991;1096:277-83
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Khayat D, Banzet P, Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990;66:1873-8
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Khayat D, Banzet P, Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990;25:263-6
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Wenzel E, Brassow FW, Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991;29:85-7
   PubMed Web of Science ®Google Scholar
• Calabresi F, Aapro M, Becquart D, Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991;2:377-8
   PubMed Web of Science ®Google Scholar
• Falkson CI, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 1994;12:251-4
   PubMed Web of Science ®Google Scholar
• Kleeberg UR, Engel E, Israels P, Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 1995;5:195-200
   PubMed Web of Science ®Google Scholar
• Avril MF, Aamdal S, Grob JJ, Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25
   PubMed Web of Science ®Google Scholar
• Avril MF, Bonneterre J, Cupissol D, Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992;28A:1807-11
   PubMed Web of Science ®Google Scholar
• Chang J, Atkinson H, A'Hern R, A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 1994;30A:2093-5
   PubMed Web of Science ®Google Scholar
• Binder M, Winkler A, Dorffner R, Fotemustine plus dacarbazine in advanced stage III malignant melanoma. Eur J Cancer 1992;28A:1814-16
   PubMedGoogle Scholar
• Seeber A, Binder M, Steiner A, Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Eur J Cancer 1998;34:2129-31
   PubMedGoogle Scholar
• Lee SM, Thatcher N, Margison GP. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991;51:619-23
   PubMed Web of Science ®Google Scholar
• Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993;67:1356-60
   PubMed Web of Science ®Google Scholar
• Aamdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma – an effective combination with unexpected toxicity. Eur J Cancer 1992;28:447-50
   PubMed Web of Science ®Google Scholar
• Rixe O, Borel C, Paraiso D, Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Melanoma Res 1995;5:419-24
   PubMed Web of Science ®Google Scholar
• McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992;50:553-6
   PubMed Web of Science ®Google Scholar
• Fierro MT, Bertero M, Novelli M, Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res 1993;3:127-31
   PubMed Web of Science ®Google Scholar
• Richard MA, Grob JJ, Zarrour H, Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Res 1998;8:170-4
   PubMedGoogle Scholar
• Semb KA, Aamdal S, Bohmann T, Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. Melanoma Res 1998;8:565-72
   PubMedGoogle Scholar
• Schadendorf D, Jurgovsky K, Worm M, Czarnetzki BM. In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons. Melanoma Res 1994;4:243-9
   PubMedGoogle Scholar
• Weichenthal M, Mohr P, Stephan U, Fotemustine and interferon alpha2b in metastatic malignant melanoma. J Cancer Res Clin Oncol 1998;124:55-9
   PubMedGoogle Scholar
• Daponte A, Ascierto PA, Gravina A, Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000;89:2630-6
   PubMedGoogle Scholar
• Comella P, Daponte A, Casaretti R, Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma. Eur J Cancer 1997;33:1326-9
   PubMedGoogle Scholar
• Terheyden P, Becker JC, Kampgen E, Brocker EB. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma. Melanoma Res 2000;10:475-82
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Fiorentini G, Guida M, Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. Melanoma Res 2009;19:100-5
   PubMed Web of Science ®Google Scholar
• Tas F, Camlica H, Topuz E. Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer Chemother Pharmacol 2008;62:293-8
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Newlands ES, Lee SM, Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-13
   PubMed Web of Science ®Google Scholar
• Guida M, Cramarossa A, Fistola E, High activity of sequential low dose chemo-modulating temozolomide in combination with fotemustine in metastatic melanoma. A feasibility study. J Transl Med 2010;8:115
   PubMedGoogle Scholar
• Del Vecchio M, Mortarini R, Canova S, Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16:5862-72
   PubMed Web of Science ®Google Scholar
• Brocker EB, Bohndorf W, Kampgen E, Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res 1996;6:399-401
   PubMed Web of Science ®Google Scholar
• Ulrich J, Gademann G, Gollnick H. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation. J Neurooncol 1999;43:173-8
   PubMedGoogle Scholar
• Mornex F, Thomas L, Mohr P, A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003;13:97-103
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, Pilati P, Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002;29:400-9
   PubMedGoogle Scholar
• Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999;36:841-907
   PubMed Web of Science ®Google Scholar
• Pontes L, Lopes M, Ribeiro M, Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. Melanoma Res 1997;7:417-19
   PubMedGoogle Scholar
• Rossi CR, Lejeune FJ, Pontes L, Phase I – II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. Melanoma Res 2003;13:293-7
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Thompson JF, de Wilt JH, Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004;30:1107-12
   PubMed Web of Science ®Google Scholar
• Leyvraz S, Spataro V, Bauer J, Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589-95
   PubMed Web of Science ®Google Scholar
• Peters S, Voelter V, Zografos L, Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006;17:578-83
   PubMed Web of Science ®Google Scholar
• Siegel R, Hauschild A, Kettelhack C, Hepatic arterial fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007;33:627-32
   PubMed Web of Science ®Google Scholar
• Mohr P, Makki A, Breitbart E, Schadendorf D. Combined treatment of stage IV melanoma patients with amifostine and fotemustine – a pilot study. Melanoma Res 1998;8:166-9
   PubMed Web of Science ®Google Scholar
• Raymond E, Haon C, Boaziz C, Coste M. Logistic regression model of fotemustine toxicity combining independent phase II studies. Cancer 1996;78:1980-7
   PubMed Web of Science ®Google Scholar